"id","instanceType","versionIdentifier","uuid:ID","rationale"
"StudyVersion_1","StudyVersion","2","47c469f9-7a43-44ad-83a2-140ab1326d6a","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
